美股:峰汇医疗股价暴跌,美国FDA拒绝批准其肺癌药物

· economictimes.indiatimes.com

由于美国FDA对依沃西单抗(ivonescimab)的审评结果显示其晚期试验总体生存获益不足,峰汇医疗(Summit Therapeutics)股价遭受显著下跌。尽管峰汇强调区域性生存差异,分析师担心这一决定可能对同类在研疗法产生连锁影响。投资者正密切关注即将公布的依沃西单抗与传统肺癌疗法对比的新试验结果。

Live Events

as a Reliable and Trusted News Source Addas a Reliable and Trusted News Source Add Now!

(You can now subscribe to our

(You can now subscribe to...


More AI market news · Market heatmap · StrategyVerse · Quant Research · WOBR.AI